Cellectis S.A.
CLLS•NASDAQ•Healthcare•Biotechnology

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOAndre Choulika
Founded1999
IPO DateFebruary 7, 2007
Employees222
CountryFrance
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.cellectis.com
Phone33 1 81 69 16 00
Address
8, rue de la Croix Jarry Paris, 75013 France

Corporate Identifiers

CIK0001627281
CUSIP15117K103
ISINUS15117K1034
SIC2836

Leadership Team & Key Executives

Dr. David J. Sourdive Ph.D.
Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC and Manufacturing and Director
Dr. Andre Choulika Ph.D.
Co-Founder, Chief Executive Officer and Director
Arthur Stril
Chief Financial Officer and Chief Business Officer
Valerie Cros
Principal Financial Officer and Principal Accounting Officer
Jean Charles Epinat Ph.D.
Chief Technological Officer
Dr. Philippe Duchateau Ph.D.
Chief Scientific Officer
Marie-Bleuenn Terrier
General Counsel and Secretary of the Board of Directors
Pascalyne Wilson
Director of Communications
Kyung Nam-Wortman
Executive Vice President and Chief Human Resources Officer
Stephan Reynier M.Sc.
Chief Regulatory and Pharmaceutical Compliance Officer